A National Adverse Drug Reaction Reporting System for Malta by Bonett, Michael et al.
Malta Medical Journal    Volume 16   Issue 03   October 2004 3 1
A National Adverse Drug Reaction
Reporting System for Malta
Michael Bonett  BPharm (Hons) *
Medicines Authority, Gzira, Malta
Email: michael.p.bonett@gov.mt
Niamh Arthur RGN, PhD
Irish Medicines Board, Ireland
Patricia Vella Bonanno BPharm (Hons), PhD
Medicines Authority, Malta
*corresponding author
Michael Bonett, Niamh Arthur, Patricia Vella Bonanno
Quality in Healthcare
Introduction
The mission of the Medicines Authority (MA) in Malta is to
contribute to protection of public health through regulation of
the safety, quality and efficacy of medicines for human use on
the local market and to ensure that healthcare professionals and
patients have access to accurate and up to date information
about medicines.  In order to disseminate information regarding
safety of medicines, the MA publishes guidance notes for
healthcare professionals and the pharmaceutical industry. The
MA also publishes information on its website:
http://www.health.gov.mt/mru/
On the 4th of May, 2004 the MA held a seminar to launch a
national adverse drug reaction (ADR) reporting system
involving the co-operation of doctors, dentists and pharmacists,
as well as the pharmaceutical industry. The ADR reporting
system will form part of an overall pharmacovigilance system
within the Authority and this will be the primary means of
collecting information useful in the surveillance of medicinal
products.
Pharmacovigilance
Pharmacovigilance is the science and activities relating to
the detection, assessment, understanding and prevention of
adverse effects of medicines and it is an important aspect of the
regulation of medicines. The overall objectives of
pharmacovigilance include early identification of potential
safety hazards, evaluation, monitoring and where appropriate,
implementation of regulatory action to maximise benefits and
minimise risks associated with medicinal products. Notification
and reporting of suspected ADRs arising with use of medicinal
products, by healthcare professionals is an essential source of
new information for the achievement of these objectives.
The need for drug safety monitoring
Not all hazards can be known before a medicinal product is
marketed. Patients, consumers and indeed some healthcare
professionals have expectations that medicinal products
available are “safe” and may be surprised when regulatory action
is taken to restrict their use, introduce new warning statements,
or withdraw medicines as a result of new information regarding
safety issues.
Information collected during the pre-marketing phase of a
medicinal product is inevitably insufficient with regard to the
complete safety profile of a product and animal testing is not
necessarily predictive of human safety. Data from clinical trials
is often limited by their size and duration and  furthermore,
conditions of use may differ during clinical trials from those
encountered during normal clinical practice. Information about
rare but serious adverse reactions, chronic toxicity, use in special
groups (such as children, the elderly or pregnant women), or
drug interactions is often incomplete or not available at all: this
emphasises the need for ongoing surveillance.
All medicines have the potential to cause ADRs. It is
estimated that ADRs cause admission to hospitals in as much
as 2% to 6% of all cases. Furthermore, ADRs contribute to an
increased attendance at  primary health care level and may
complicate hospital in-patient stay in as many as 10% to 20% of
patients.1 Moreover, ADRs may be responsible for deaths and
they may possibly be the fourth commonest cause of death.  They
may increase the length of hospital stay and therefore increase
the cost of patient care. In addition ADRs may adversely affect
quality of life and may cause patients to lose confidence in
doctors.1
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ADRs also mimic disease and result in unnecessary
investigations and possibly delay accurate diagnosis and
treatment. As a corollary, occurrence of toxicity in a minority of
patients might preclude use of an important medicinal product
in the majority of patients, if predisposing factors cannot be
identified and appropriate regulatory measures implemented
to appropriately manage their risks.
Development of ADR reporting systems
Perhaps the greatest of all drug disasters was the
thalidomide tragedy of 1961-1962, when thalidomide caused
major birth defects in an estimated 10 000 children in the
countries in which it was widely used for the treatment of nausea
and vomiting in early pregnancy. The thalidomide disaster led
to the establishment of drug regulation in many countries
around the world. Such regulation requires that medicinal
products are licensed by an established regulatory authority.2
The history of international pharmacovigilance goes back
to when the Twentieth World Health Assembly adopted a
resolution to start a project on the feasibility of an international
system for monitoring adverse reactions to drugs. This
resolution was the basis of the WHO Programme for
International Drug Monitoring of 1968. Since then, many
countries have established pharmacovigilance systems and there
are now over 70 countries involved in the WHO Collaborating
Programme for International Drug Monitoring. 3  The
establishment of a functional ADR reporting system not only
facilitates participation in the national and EU regulatory
process, but also enables Malta to participate in the WHO
Programme for International Drug Monitoring, both by
contributing to and obtaining data from this extensive
information resource.
Legislation
The adverse drug reaction reporting system established in
Malta is consistent with requirements established by European
and Maltese legislation for the regulation of medicinal products.
European legislation relating to the regulation of medicinal
products for human use is embodied in Directive 2001/83/EC,
recently revised and replaced by Directive 2004/27/EC. This
Directive lays down requirements not only for persons
marketing medicinal products in EU Member States but also
for competent authorities . Competent Authorities in Member
States, such as the Medicines Authority in Malta, ‘shall establish
a pharmacovigilance system – this system shall be used to collect
information useful for the surveillance of medicinal products,
with particular reference to adverse reactions in human beings
and to evaluate such information scientifically.’ 4  Member States
are also obliged to  ‘take all appropriate measures to encourage
doctors and other healthcare professionals to report suspected
adverse reactions to the competent authorities.’ 4
In addition, the competent authority of the Member State
should  ‘suspend or revoke an authorization to place a medicinal
product on the market where that product proves to be harmful
in the normal conditions of use, or where therapeutic efficacy is
lacking, or where qualitative and quantitative composition is
not declared.’ 4
In November 2003, a new Medicines Act was published,
replacing previous legislation. This Act established the
regulatory framework for the Medicines Authority and further
subsidiary legislation to the Medicines Act for
pharmacovigilance was published in Legal Notice 22 of 2004.
The Maltese pharmacovigilance regulations state that: ‘It shall
be the duty of doctors and other healthcare professionals to
report to the Authority any suspected serious or unexpected
adverse reaction to a medicinal product’.2
The role of health care professionals
In all countries, where pharmacovigilance systems operate,
the role of healthcare professionals is vital in recording and
reporting suspected ADRs observed in their practice, in order
to alert regulatory agencies to new or emerging safety concerns,
thus facilitating timely and appropriate regulatory action. The
advantages of an ADR reporting system are:
• It is an inexpensive method of monitoring the safety of a
medicinal product throughout its lifetime.
• Reports are based on unbiased observations made by
vigilant healthcare professionals.
• It is an essential method of detecting signals of rare ADRs.
• It remains the primary method of data-collection used in
most countries.
Participation of healthcare professionals is therefore
essential for the effective functioning of a pharmacovigilance
system and the reporting system introduced in Malta is a
mandatory, country-wide system for the reporting of suspected
ADRs.
How to report
For the purposes of reporting, an ADR reporting form has
been designed and copies  are available from the MA, and may
be downloaded from http://www.health.gov.mt/mru/  Receipt
of any ADR forms sent to the MA will be acknowledged and the
minimum information required for a valid report is:
• An identifiable reporter, (e.g. doctor, pharmacist, dentist)
• An identifiable patient (e.g. initials, age, sex)
• A suspected medicinal product
• A suspected ADR
 Information contained in ADR reports will be entered on
the MA’s secure database and all personal data will be treated
as confidential.
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What to report
The legal obligation contained in Legal Notice 22 of 2004
and described previously, specifies the obligation for healthcare
professionals to report to the Authority any suspected serious
or unexpected ADR to a medicinal product.   A serious  ADR is
one that is:
• Fatal
• Life threatenting
• Causes or prolongs hospitalization
• Causes a congenital abnormality
• Causes disability or incapacity
An unexpected adverse drug reaction is one whose nature,
severity or outcome is not consistent with the summary of
product characteristics.4 However, healthcare professionals are
also encouraged to report all suspected ADRs to the MA. In
addition to data provided by healthcare professionals,
pharmaceutical companies will also be obliged to provide
pharmacovigilance data to the MA as a condition of their licence
to market medicinal products.
Evaluation of data by the MA
ADR reports will be assessed in the context of other available
data and MA staff will regularly review safety issues internally
and with national experts and professional associations.  In
addition, MA staff will participate in scientific meetings that
consider safety issues, such as the Pharmacovigilance Working
Party of the Committee for Human Medicinal Products.
Implementation of regulatory action
As a result of the evaluation of pharmacovigilance data and
in keeping with national and EU legislation, the MA may take
regulatory action to vary, suspend or withdraw marketing
authorisations for  medicinal products, if considered
appropriate.
Regulatory measures will be taken in order to prevent future
serious ADRs, and to minimize the risks associated with use of
medicinal products. When changes to product information are
made to enhance safety, these will be communicated to
healthcare professionals.  Regular updates on important safety
issues will be provided to healthcare professionals through a
Newsletter issued by the MA, which will be published and
distributed at regular intervals throughout the year. In urgent
cases, specific letters would be sent to alert healthcare
professionals of a new or  emerging safety concern.
The MA will also have a role as an information service
provider to healthcare professionals by making available the
latest up-to-date drug safety information.
Conclusion
On-going monitoring of the safety of medicinal products is
an essential component of pharmacovigilance and is a
responsibility shared by healthcare professionals, the
pharmaceutical industry and the MA, to ensure availability of
complete, up-to-date safety information which in turn
minimises individual patient risks.
The essential aim of legislation governing the production,
distribution and use of medicinal products is to safeguard public
health and EU legislation provides a framework that must be
adopted by all member states.  Implementation of EU and
national legislation is without doubt a further step in ensuring
availability of safe, efficacious and good quality medicinal
products in Malta, in the interest of public health.  The
establishment of the MA as an EU competent authority, should
contribute to improved patient care and safety and facilitate
the overall assessment of medicinal products.
It is also hoped that establishment of the MA will enhance
promotion of understanding and knowledge of healthcare
professionals regarding safe use of medicinal products and
provide an effective means of communication to both healthcare
professionals and to the public.
Since the launch, the MA has already received and processed
several suspected ADR reports and through such reporting,
healthcare professionals make a positive contribution to the
overall knowledge of the safety profile of medicines and to the
national pharmacovigilance system.
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